Drug:
Reaction: INJECTION SITE ERYTHEMA
20260101 - 20261231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 26484192 |
US |
17 | 1 |
Viral infection, Pyrexia, Off label use, Lethargy, Dizziness, Injection site pain, Injection site erythema, Injection site warmth, Injection site bruising, |
||||
PEGVALIASE-PQPZ, |
||||
| 302 | 26484387 |
US |
70 | 2 |
Constipation, Injection site erythema, Injection site inflammation, Injection site pruritus, Injection site swelling, Injection site discolouration, Gastrooesophageal reflux disease, Fatigue, |
||||
TIRZEPATIDE, TIRZEPATIDE, POLYETHYLENE GLYCOL 3350, HYDROCHLOROTHIAZIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, PSYLLIUM HUSK, |
||||
| 303 | 26484522 |
US |
1 | |
Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 304 | 26484561 |
US |
2 | |
Injection site erythema, Injection site pruritus, Injection site swelling, Drug ineffective, |
||||
DUPILUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, |
||||
| 305 | 26484599 |
US |
2 | |
Injection site haemorrhage, Device issue, Injection site erythema, |
||||
ADALIMUMAB, |
||||
| 306 | 26485122 |
US |
18 | |
Injection site pruritus, Injection site erythema, |
||||
INFLIXIMAB-DYYB, |
||||
| 307 | 26485143 |
US |
52 | |
Injection site swelling, Injection site erythema, |
||||
INFLIXIMAB-DYYB, |
||||
| 308 | 26475970 |
43 | ||
Injection site erythema, Injection site induration, Injection site discolouration, |
||||
OLEZARSEN SODIUM, DICLOFENAC, DICLOFENAC SODIUM, EVOLOCUMAB, FENOFIBRATE, GABAPENTIN, INSULIN ASPART, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, LOSARTAN, MECLIZINE HCL 12.5 MG, MECLIZINE HCL 25 MG, MECLIZINE HYDROCHLORIDE, MECLIZINE, MECLIZINE HCL 25MG, MECLIZINE HCL 12.5MG, NIACIN, CYCLOBENZAPRINE, NALOXONE HCL, |
||||
| 309 | 26476364 |
US |
1 | |
Injection site erythema, |
||||
OCRELIZUMAB AND HYALURONIDASE, |
||||
| 310 | 26477139 |
US |
2 | |
Injection site erythema, Injection site swelling, Injection site induration, Injection site discomfort, |
||||
ROMOSOZUMAB-AQQG, |
||||
| 311 | 26477720 |
US |
58 | 2 |
Dizziness, Weight increased, Injection site erythema, Injection site pain, |
||||
| 312 | 26477728 |
US |
30 | 1 |
Injection site erythema, Injection site pain, Injection site discolouration, Injection site discharge, Underdose, |
||||
| 313 | 26477750 |
US |
39 | |
Injection site pain, Injection site erythema, Injection site swelling, |
||||
INFLIXIMAB-DYYB, |
||||
| 314 | 26478676 |
US |
74 | 2 |
Injection site pain, Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 315 | 26478741 |
US |
||
Injection site pruritus, Injection site hypersensitivity, Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 316 | 26478893 |
US |
83 | 1 |
Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 317 | 26479229 |
US |
62 | 2 |
Injection site erythema, Off label use, |
||||
ADALIMUMAB-ADBM, |
||||
| 318 | 26479809 |
US |
62 | 2 |
Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 319 | 26479872 |
US |
1 | |
Device alarm issue, Injection site erythema, Injection site injury, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 320 | 26471481 |
US |
||
Injection site pruritus, Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 321 | 26471542 |
US |
59 | 2 |
Injection site hypersensitivity, Injection site warmth, Injection site erythema, Incorrect dose administered by device, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 322 | 26471729 |
US |
2 | |
Injection site erythema, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 323 | 26472495 |
US |
64 | 1 |
Drug ineffective, Injection site swelling, Injection site pain, Injection site erythema, |
||||
TRALOKINUMAB-LDRM, |
||||
| 324 | 26472603 |
US |
79 | 2 |
Injection site rash, Injection site erythema, Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 325 | 26472854 |
JP |
76 | 2 |
Empyema, Needle track marks, Blood pressure decreased, Skin papilloma, Pyrexia, Hyperhidrosis, Pyrexia, Tympanic membrane perforation, Pharyngeal polyp, Injection site haemorrhage, Injection site swelling, Injection site erythema, Injection site pain, Vertigo, |
||||
ABALOPARATIDE, ABALOPARATIDE, |
||||
| 326 | 26473063 |
CN |
28 | 2 |
Injection site erythema, Injection site swelling, Drug hypersensitivity, |
||||
CARBOPROST TROMETHAMINE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, CEFOXITIN SODIUM, OXYTOCIN, |
||||
| 327 | 26474061 |
US |
60 | 2 |
Colitis ulcerative, Therapeutic reaction time decreased, Defaecation urgency, Diarrhoea, Flatulence, Injection site erythema, Injection site pruritus, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 328 | 26474194 |
US |
2 | |
Injection site erythema, Injection site pruritus, |
||||
| 329 | 26474444 |
US |
48 | 2 |
Arthralgia, Peripheral swelling, Pain in extremity, Injection site erythema, |
||||
PEGVALIASE-PQPZ, PEGVALIASE-PQPZ, |
||||
| 330 | 26474448 |
US |
4 | 2 |
Injection site pruritus, Injection site erythema, |
||||
| 331 | 26474681 |
US |
55 | 2 |
Rash papular, Injection site erythema, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 332 | 26475457 |
|||
Injection site rash, Injection site erythema, |
||||
BIMEKIZUMAB, |
||||
| 333 | 26470634 |
US |
33 | 2 |
Incorrect dose administered by device, Injection site pain, Injection site erythema, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 334 | 26470688 |
US |
60 | |
Injection site pain, Injection site urticaria, Injection site erythema, Device delivery system issue, |
||||
SUMATRIPTAN SUCCINATE, BUPROPION, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, LOSARTAN, |
||||
| 335 | 26470707 |
US |
60 | 2 |
Injection site pruritus, Injection site erythema, Injection site mass, |
||||
TIRZEPATIDE, |
||||
| 336 | 26470747 |
US |
72 | 2 |
Injection site erythema, Injection site pruritus, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 337 | 26470753 |
US |
67 | |
Product administered at inappropriate site, Incorrect dose administered, Injection site erythema, Injection site bruising, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 338 | 26470776 |
US |
51 | 2 |
Visual impairment, Injection site swelling, Injection site erythema, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, |
||||
| 339 | 26470933 |
US |
74 | 2 |
Injection site discolouration, Injection site haemorrhage, Injection site bruising, Injection site mass, Injection site erythema, |
||||
DULAGLUTIDE, |
||||
| 340 | 26470980 |
US |
2 | |
Injection site swelling, Injection site erythema, |
||||
GUSELKUMAB, |
||||
| 341 | 26471009 |
US |
57 | 1 |
Injection site warmth, Injection site erythema, |
||||
PEGINTERFERON BETA-1A, |
||||
| 342 | 26471054 |
39 | ||
Injection site erythema, Injection site swelling, Pain, Erythema, Swelling, Illness, |
||||
BIMEKIZUMAB, |
||||
| 343 | 26470574 |
US |
58 | 2 |
Injection site erythema, Injection site pain, Injection site swelling, Incorrect dose administered, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 344 | 26466753 |
CA |
45 | |
Lower respiratory tract infection, Nasopharyngitis, Dizziness, Injection site swelling, Injection site erythema, Injection site pruritus, Product dose omission issue, Inappropriate schedule of product administration, |
||||
OMALIZUMAB, OMALIZUMAB, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 345 | 26467219 |
US |
52 | 2 |
Injection site erythema, Injection site swelling, Injection site pain, |
||||
ABATACEPT, SARILUMAB, |
||||
| 346 | 26467560 |
US |
36 | 2 |
Pyrexia, Injection site pain, Injection site erythema, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, RIMEGEPANT SULFATE, |
||||
| 347 | 26468073 |
IL |
2 | |
Pneumonia, Injection site swelling, Injection site erythema, Injection site pruritus, |
||||
VEDOLIZUMAB, |
||||
| 348 | 26468204 |
IL |
47 | 2 |
Osteoporosis, Injection site swelling, Injection site rash, Injection site pruritus, Accidental exposure to product, Device leakage, Migraine, Injection site erythema, |
||||
FREMANEZUMAB-VFRM, |
||||
| 349 | 26468271 |
US |
44 | 1 |
Adverse drug reaction, Injection site rash, Injection site erythema, Injection site pain, Injection site warmth, |
||||
| 350 | 26468512 |
US |
19 | 2 |
Injection site erythema, |
||||
| 351 | 26468517 |
US |
22 | 2 |
Injection site hypersensitivity, Injection site erythema, Injection site swelling, |
||||
PEGVALIASE-PQPZ, FAMOTIDINE, CETIRIZINE HYDROCHLORIDE, MONTELUKAST, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 352 | 26468801 |
US |
66 | 2 |
Injection site papule, Injection site erythema, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 353 | 26469227 |
US |
22 | 2 |
Injection site erythema, |
||||
GALCANEZUMAB-GNLM, CELECOXIB, |
||||
| 354 | 26460958 |
CA |
||
Cataract, Death of relative, Diverticulitis, Drug eruption, Hepatic enzyme increased, Infusion site erythema, Infusion site urticaria, Injection site erythema, Injection site pruritus, Leiomyosarcoma, Ocular discomfort, Osteoarthritis, Pulmonary embolism, Reaction to excipient, Weight decreased, White coat hypertension, Inappropriate schedule of product administration, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, PREDNISONE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, ESTRADIOL, EZETIMIBE, BIMATOPROST, RAMIPRIL, RAMIPRIL, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, ROSUVASTATIN CALCIUM, |
||||
| 355 | 26461167 |
US |
71 | 2 |
Injection site erythema, |
||||
TIRZEPATIDE, |
||||
| 356 | 26461301 |
US |
36 | 2 |
Skin reaction, Injection site erythema, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 357 | 26461876 |
US |
41 | 2 |
Injection site swelling, Injection site erythema, |
||||
FREMANEZUMAB-VFRM, FREMANEZUMAB-VFRM, |
||||
| 358 | 26462003 |
US |
44 | 2 |
Injection site erythema, Accidental exposure to product, Injection site swelling, Device malfunction, |
||||
FREMANEZUMAB-VFRM, |
||||
| 359 | 26462474 |
|||
Hypersensitivity, Injection site pain, Injection site erythema, Injection site warmth, Injection site urticaria, Drug ineffective, |
||||
BIMEKIZUMAB, |
||||
| 360 | 26462690 |
76 | ||
Cataract, Cataract operation, Injection site hypersensitivity, Fall, Peripheral swelling, Pain in extremity, Injection site erythema, Injection site pruritus, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, ROSUVASTATIN, INDAPAMIDE, |
||||
| 361 | 26462695 |
63 | 2 | |
Injection site erythema, Injection site pruritus, Injection site warmth, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, MODAFINIL, DULOXETINE HYDROCHLORIDE, DULOXETINE, BREXPIPRAZOLE, LIOTHYRONINE SODIUM, GABAPENTIN, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, CELECOXIB, IRON, ERGOCALCIFEROL, BIOTIN, |
||||
| 362 | 26462803 |
|||
Injection site irritation, Injection site erythema, |
||||
BIMEKIZUMAB, SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 363 | 26463511 |
US |
8 | 2 |
Apnoea, Nasal congestion, Injection site erythema, Injection site urticaria, Injection site erythema, |
||||
ERGOCALCIFEROL, FAMOTIDINE, |
||||
| 364 | 26463883 |
US |
||
Injection site pain, Injection site bruising, Injection site erythema, Injection site warmth, Injection site inflammation, Cellulitis, Abdominal wall wound, |
||||
LENACAPAVIR SODIUM, LENACAPAVIR SODIUM, LENACAPAVIR SODIUM, LENACAPAVIR SODIUM, AMOXICILLIN, |
||||
| 365 | 26465068 |
US |
55 | 2 |
Injection site warmth, Injection site erythema, Injection site pruritus, Injection site induration, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 366 | 26457686 |
US |
72 | 2 |
Injection site erythema, Injection site irritation, |
||||
TIRZEPATIDE, |
||||
| 367 | 26457696 |
US |
65 | 2 |
Injection site bruising, Injection site haemorrhage, Injection site erythema, Injection site pain, Device issue, |
||||
GABAPENTIN, CLONAZEPAM, PANTOPRAZOLE, CELECOXIB, CETIRIZINE HYDROCHLORIDE, BUPROPION, OXYCODONE, FAMOTIDINE, METOPROLOL TARTRATE, METOPROLOL, LOSARTAN, ATORVASTATIN CALCIUM, PROPRANOLOL HYDROCHLORIDE, LEVOTHYROXINE SODIUM, |
||||
| 368 | 26459939 |
US |
55 | 1 |
Blindness unilateral, Peripheral swelling, Uveitis, Arthralgia, Conjunctivitis, Injection site pain, Injection site erythema, Arthritis, |
||||
ADALIMUMAB, |
||||
| 369 | 26460148 |
GB |
||
Syncope, Emotional distress, Blood glucose decreased, Hypotension, Dizziness, Injection site erythema, Injection site pruritus, Injection site rash, Injection site inflammation, Dehydration, Abdominal pain upper, Asthenia, Malaise, Nausea, Eructation, Vomiting, Diarrhoea, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 370 | 26452854 |
US |
2 | |
Injection site erythema, Drug delivery system malfunction, |
||||
PEGINTERFERON BETA-1A, PEGINTERFERON BETA-1A, PEGINTERFERON BETA-1A, NAPROXEN, NAPROXEN SODIUM, ERGOCALCIFEROL, |
||||
| 371 | 26453074 |
|||
Psoriasis, Surgery, Injection site erythema, Memory impairment, Skin fissures, Hordeolum, Therapeutic response shortened, Therapy interrupted, Insurance issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 372 | 26453076 |
US |
76 | 2 |
Injection site swelling, Injection site erythema, Drug ineffective, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 373 | 26453207 |
US |
81 | 2 |
Injection site erythema, Injection site swelling, |
||||
IXEKIZUMAB, |
||||
| 374 | 26453328 |
US |
50 | 2 |
Injection site erythema, Injection site pruritus, Injection site urticaria, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 375 | 26453467 |
24 | ||
Injection site pain, Premature delivery, Pyrexia, Immunosuppression, Gastroenteritis, Leukopenia, Staphylococcal infection, Cholestasis of pregnancy, Hypersensitivity, Injection site erythema, Injection site bruising, Pain, Fungal infection, Ovarian cyst, Injection site haematoma, Headache, Myalgia, Photophobia, Caesarean section, Maternal exposure during pregnancy, Maternal exposure before pregnancy, Product use in unapproved indication, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, PREDNISONE, PREDNISONE, CAFFEINE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, METRONIDAZOLE, METRONIDAZOLE TOPICAL, MORPHINE, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, |
||||
| 376 | 26453756 |
US |
72 | 2 |
Injection site erythema, Nausea, Vomiting, Decreased appetite, White blood cell count increased, |
||||
GUSELKUMAB, VALPROIC ACID, QUETIAPINE, |
||||
| 377 | 26454962 |
|||
Injection site erythema, Wrong technique in product usage process, |
||||
BIMEKIZUMAB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, LOSARTAN POTASSIUM, LOSARTAN, CALCIUM, |
||||
| 378 | 26455553 |
US |
52 | 2 |
Injection site pain, Injection site swelling, Injection site erythema, |
||||
| 379 | 26455570 |
59 | 2 | |
Illness, Injection site erythema, Injection site warmth, Injection site swelling, Injection site pruritus, Injection site pain, |
||||
REPOSITORY CORTICOTROPIN, |
||||
| 380 | 26455685 |
US |
63 | 2 |
Injection site erythema, Injection site warmth, Injection site pain, |
||||
PREDNISONE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, PREDNISONE, |
||||
| 381 | 26455904 |
US |
62 | 2 |
Injection site reaction, Injection site rash, Injection site erythema, Injection site bruising, Injection site pruritus, |
||||
PEGVALIASE-PQPZ, |
||||
| 382 | 26456094 |
US |
87 | 2 |
Injection site pain, Product communication issue, Fear of injection, Device difficult to use, Drug dose omission by device, Injection site erythema, |
||||
EVOLOCUMAB, EVOLOCUMAB, CLOPIDOGREL, |
||||
| 383 | 26456262 |
US |
2 | |
Blister, Injection site bruising, Injection site erythema, Injection site irritation, Injection site pain, Off label use, Product quality issue, |
||||
METHOTREXATE, ADALIMUMAB, |
||||
| 384 | 26456339 |
GB |
2 | |
Food allergy, Injection site swelling, Injection site rash, Injection site pruritus, Drug hypersensitivity, Injection site erythema, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 385 | 26448446 |
US |
||
Vomiting, Decreased appetite, Injection site erythema, |
||||
BUROSUMAB, |
||||
| 386 | 26448564 |
US |
1 | |
Injury associated with device, Injection site erythema, Injection site swelling, |
||||
ERENUMAB-AOOE, |
||||
| 387 | 26448797 |
US |
40 | 2 |
Injection site bruising, Injection site erythema, Injection site rash, |
||||
BELIMUMAB, |
||||
| 388 | 26448938 |
US |
54 | |
Injection site erythema, Injection site pruritus, Injection site irritation, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 389 | 26449496 |
GB |
32 | 2 |
Syncope, Pallor, Loss of consciousness, Eye movement disorder, Dystonia, Muscle rigidity, Bruxism, Disorientation, Illness, Vomiting, Nausea, Injection site erythema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 390 | 26449957 |
US |
||
Accidental overdose, Product preparation issue, Injection site pain, Injection site erythema, Injection site pruritus, |
||||
TESAMORELIN, |
||||
| 391 | 26450243 |
US |
71 | 2 |
Injection site pruritus, Injection site erythema, Injection site inflammation, |
||||
TIRZEPATIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, AMLODIPINE, HYDROCHLOROTHIAZIDE, THYROID, PORCINE, |
||||
| 392 | 26450567 |
US |
2 | |
Sinusitis, Accidental exposure to product, Device use error, Drug dose omission by device, Device difficult to use, Product communication issue, Injection site erythema, Injection site haemorrhage, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 393 | 26450769 |
US |
2 | |
Injection site pruritus, Formication, Injection site erythema, |
||||
PEGVALIASE-PQPZ, PEGVALIASE-PQPZ, |
||||
| 394 | 26450816 |
US |
2 | |
Injection site erythema, Injection site pruritus, Injection site swelling, |
||||
| 395 | 26451126 |
US |
2 | |
Injection site erythema, Injection site pruritus, Injection site nodule, Incorrect dose administered, |
||||
GUSELKUMAB, |
||||
| 396 | 26451615 |
6 | 1 | |
Papule, Injection site erythema, Immunisation reaction, Injection site induration, |
||||
NIRSEVIMAB, |
||||
| 397 | 26451694 |
US |
2 | |
Wrong technique in product usage process, Injection site erythema, Injection site reaction, Injection site haemorrhage, Injection site bruising, |
||||
ADALIMUMAB, ETANERCEPT, |
||||
| 398 | 26451885 |
US |
57 | 2 |
Injection site erythema, Injection site induration, |
||||
TIRZEPATIDE, ATENOLOL, |
||||
| 399 | 26452007 |
US |
2 | |
Injection site erythema, Injection site pruritus, Urticaria, Injection site mass, |
||||
TOCILIZUMAB, |
||||
| 400 | 26452196 |
US |
53 | 1 |
Injection site pain, Injection site erythema, |
||||
NIVOLUMAB AND HYALURONIDASE-NVHY, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28